Use of methotrexate in patients with systemic lupus erythematosus and primary Sjögren's syndrome

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Winzer, M ^a   Aringer, M ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Methotrexate; Sj gren's syndrome; Systemic lupus erythematodes

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; METHOTREXATE; AUTOANTIBODY; PLACEBO; PREDNISONE;

ARTHRITIS; ARTICLE; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; INFLAMMATION; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MYOSITIS; NEUROPSYCHIATRIC LUPUS; PANCYTOPENIA; PRIORITY JOURNAL; SIDE EFFECT; SJOEGREN SYNDROME; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; ANTIBODY DETECTION; CLINICAL FEATURE; DENDRITIC CELL; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; HEMOLYTIC ANEMIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MACROPHAGE; MEDICAL SOCIETY; PREVALENCE; THROMBOCYTOPENIA;

ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHOTREXATE; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 78650532904     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. RAHMAN A, ISENBERG DA: Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
2. ARINGER M, SMOLEN JS: Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004;13:344-7.
3. BERTSIAS G, IOANNIDIS JP, BOLETIS J et al.: EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205.
4. CARNEIRO JR, SATO EI: Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999;26:1275-9.
5. FORTIN PR, ABRAHAMOWICZ M, FERLAND D, LACAILLE D, SMITH CD, ZUMMER M: Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a doubleblind, randomized, placebo-controlled trial. Arthritis Rheum 2008;59:1796-804.
6. SATO EI: Methotrexate therapy in systemic lupus erythematosus. Lupus 2001;10:162-4.
7. WONG JM, ESDAILE JM: Methotrexate in systemic lupus erythematosus. Lupus 2005;14:101-5.
8. BAUERNFEIND B, ARINGER M, PRODINGER B et al.: Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. Arthritis Rheum 2009;61:21-8.
9. HOPKINSON ND, DOHERTY M, POWELL RJ: Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann Rheum Dis 1994;53:675-80.
10. WEINBLATT ME, COBLYU JS, FOX DA et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
11. O'DELL JR, HAIRE CE, ERIKSON N et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
12. WILLKENS RF, WILLIAMS HJ, WARD JR et al.: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
13. WISE CM, VUYYURU S, ROBERTS WN: Methotrexate in nonrenal lupus and undifferentiated connective tissue disease-a review of 36 patients. J Rheumatol 1996;23:1005-10.
14. GANSAUGE S, BREITBART A, RINALDI N, SCHWARZ-EYWILL M: Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997;56:382-5.
15. RAHMAN P, HUMPHREY-MURTO S, GLADMAN DD, UROWITZ MB: Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol 1998;25:243-6.
16. RATH E, KUDRA M, STEINER G, SMOLEN J, ARINGER M: Lupus arthritis and DMARDS - A historical prospective analysis. Ann Rheum Dis 2010;69(Suppl. 3):685.
17. ROTHENBERG RJ, GRAZIANO FM, GRANDONE JT, GOLDBERG JW, BJARNASON DF, FINESILVER AG: The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 1988;31:612-5.
18. KUHN A, BECKER-WEGERICH PM, RUZICKA T, LEHMANN P: Successful treatment of discoid lupus erythematosus with argon laser. Dermatology 2000;201:175-7.
19. WENZEL J, BRAHLER S, BAUER R, BIEBER T, TUTING T: Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005;153:157-62.
20. WENZEL J: Methotrexate in systemic lupus erythematosus. Lupus 2005;14:569.
21. BOTTOMLEY WW, GOODFIELD M: Methotrexate for the treatment of severe mucocutaneous lupus erythematosus. Br J Dermatol 1995;133:311-4.
22. MALCANGI G, BRANDOZZI G, GIANGIACOMI M, ZAMPETTI M, DANIELI MG: Bullous SLE: response to methotrexate and relationship with disease activity. Lupus 2003;12:63-6.
23. GELBER AC: Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2009;360:1358-9; author reply 1359.
24. CAMELLINO D, MORBELLI S, SAMBUCETI G, CIMMINO MA: Methotrexate treatment of polymyalgia rheumatica/giant cell arteritisassociated large vessel vasculitis. Clin Exp Rheumatol 2010;28:288-9.
25. MAHR AD, JOVER JA, SPIERA RF et al.: Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data metaanalysis. Arthritis Rheum 2007;56:2789-97.
26. BERTSIAS GK, IOANNIDIS JP, ARINGER M et al.: EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis; 2010 Aug. 19 [Epub ahead of print].
27. WISE MP, MANFORD M, DAVIES UM: Systemic lupus erythematosus presenting as fulminating cerebral lupus. Lancet 1995;345:459-60.
28. VALESINI G, PRIORI R, FRANCIA A et al.: Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol 1994;16:313-21.
29. DONG Y, ZHANG X, TANG F, TIAN X, ZHAO Y, ZHANG F: Intrathecal injection with methotrexate plus dexamethasone in the treatment of central nervous system involvement in systemic lupus erythematosus. Chin Med J (Engl) 2001;114:764-6.
30. VAN EDE AE, LAAN RF, ROOD MJ et al.: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
31. DUBOIS EL, WIERZCHOWIECKI M, COX MB, WEINER JM: Duration and death in systemic lupus erythematosus. An analysis of 249 cases. Jama 1974;227:1399-402.
32. LEBLANC BA, UROWITZ MB, GLADMAN OD: Serologically active, clinically quiescent systemic lupus erythematosus-longterm followup. J Rheumatol 1994;21:174-5.
33. YEE NS, SCHUSTER SJ: Clinical remission of acquired thrombasthenia with low-dose methotrexate in a patient with systemic lupus erythematosus. Mayo Clin Proc 2006;81:566-7.
34. RAVELLI A, BALLARDINI G, VIOLA S, VILLA I, RUPERTO N, MARTINI A: Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus. J Rheumatol 1998;25:572-5.
35. ABUD-MENDOZA C, STURBAUM AK, VAZQUEZ-COMPEAN R, GONZALEZ-AMARO R: Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 1993;20:731-3.
36. SKOPOULI FN, JAGIELLO P, TSIFETAKI N, MOUTSOPOULOS HM: Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol 1996;14:555-8.
37. MOSCA M, RUIZ-IRASTORZA G, KHAMASHTA MA, HUGHES GR: Treatment of systemic lupus erythematosus. Int Immunopharmacol 2001;1:1065-75.